This is a working overview of GHRH analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-28 and is reviewed periodically as new material appears.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Directed by David Cohen, made by Psychology News 7 November Life and Art, about assisted reproductive technology (ART) and zygote intrafallopian transfer; Debra Hauer gives a talk at Acland Burghley School; Hossam Abdalla (now on the Human Tissue Authority at the Lister Hospital, Chelsea; the assisted zona hatching technique; intracytoplasmic sperm injection; Robert Winston, Baron Winston of Hammersmith Hospital. Directed by Debra Hauer, produced by Christopher Rawlence, made by Hauer Rawlence 21 November Building for Earthquakes, earthquake engineering in Mexico City; Edward Bortugno of the Office of Emergency Services, California; structural engineer Enrique Martinez Romero of Mexico, and the building of the Mexican Social Security Institute; an earthquake was expected near Acapulco in the next ten years; the North Anatolian Fault is the world's most energetic fault; seismologist Polat Gulkan of the Middle East Technical University; Attilla Ansal, editor of the Bulletin of Earthquake Engineering; Müzeher Erciyastepe of the İnşaat Mühendisleri Odası (IMO, Chamber of Engineers); the gecekondu unsafe buildings; the recent 1992 Erzincan earthquake. Narrated by Seán Barrett (actor), directed by Nick Read, produced by Bill Redway, made by October Films 28 November Space Shuttle Discovery, the Johnson Space Center in Texas, and the ACTS satellite (launched in September 1993 on STS-51) and the shuttle pallet satellite (SPAS) system; the 57th mission of the shuttle - STS-51; Commander Frank L.
A. Ajayaghosh, born on 30 July 1962 in Kollam in the south Indian state of Kerala, graduated in science from the University of Kerala and completed his master's degree from Calicut university in 1984. Subsequently, working under the guidance of Prof. V. N. Rajasekharan Pillai, he secured a Ph.D. from University of Calicut in 1989; his thesis was on Solid-Phase Peptide Synthesis. His career started in 1988 at the Regional Research Laboratory, presently the National Institute for Interdisciplinary Science and Technology (NIIST), of the Council of Scientific and Industrial Research, as a Scientist and held various positions before promoting to an Outstanding Scientist (Scientist-H) and the head of the Photosciences and Photonics Group of NIIST. Subsequently he became the head of the Chemical Sciences and Technology group He was the director of the Institute from 2015 and held the additional responsibility as the Dean of Chemical Sciences, Academy of Scientific and Innovative Research (AcSIR) New Delhi. In between, he was as an Alexander von Humboldt Fellow at the Max Planck Institute for Strahlen Chemie, Germany during 1994–96. He served as an adjunct professor of Material Science Programme at the Indian Institute of Technology, Kanpur. Presently, he is a J. C. Bose National Fellow at CSIR-NIIST and an adjunct professor at IISER Thiruvananthapuram. Ajayaghosh is married to Ambili, and together they have two children, one of whom is Anantharaman Ajay, known for his roles in the 2023 movie "Romancham", Gaganachari, and the YouTube channel "Appooppan and the Boys","Nissaram".
== Use and effects == Salvinorin A is active at doses as low as 200 μg. It has only been administered to humans in a few studies, one showing that its effects peaked at about 2 minutes, that its subjective effects may overlap with those of serotonergic psychedelics, and that it temporarily impairs recall and recognition memory. Like most other agonists of KOR, salvinorin A produces sedation, psychotomimesis, dysphoria, anhedonia, and depression.
Proglumide, sold under the brand name Milid, is a drug that inhibits gastrointestinal motility and reduces gastric secretions. It acts as a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. It was used mainly in the treatment of stomach ulcers, although it has now been largely replaced by newer drugs for this application. An interesting side effect of proglumide is that it enhances the analgesia produced by opioid drugs, and can prevent or even reverse the development of tolerance to opioid drugs. This can make it a useful adjuvant treatment to use alongside opioid drugs in the treatment of chronic pain conditions such as cancer, where opioid analgesics may be required for long periods and development of tolerance reduces clinical efficacy of these drugs. Proglumide has also been shown to act as a δ-opioid receptor (DOR) agonist, which may contribute to its analgesic effects. However, other studies show that proglumide has low affinity to the μ-opioid receptor (MOR) and the κ-opioid receptor (KOR) (13% of MOR and 17% of KOR occupancy at 100 μM), but no affinity to DOR. It is questionable whether this is clinically significant, since the concentration they used was very high, and the occupancies were low even at that point. Proglumide also works as a placebo effect amplifier for pain conditions. When injected visibly to a subject, its analgesic effect is bigger than a similarly administered placebo.
==== Hydration ==== Increasing water intake can reduce weight by increasing thermogenesis, by reducing food intake, and by increasing fat oxidation. Persons dieting for weight loss have demonstrated the weight-reducing effects of increased water consumption. Among adults in the U.S. there is a significant association between inadequate hydration and obesity.
Sources: en.wikipedia.org
=== Sedation === Since trazodone may impair the mental or physical abilities required for the performance of potentially hazardous tasks, such as operating an automobile or machinery, the patient should be cautioned not to engage in such activities while impaired. Compared to the reversible MAOI antidepressant drug moclobemide, more impairment of vigilance occurs with trazodone. Trazodone has been found to impair driving ability.
On 22 October, Trump said that he planned to also order strikes on land targets. The Wall Street Journal reported on 30 October 2025 that the US had identified land "targets that sit at the nexus of the drug gangs and the Maduro regime", including facilities such as ports and airstrips that the Venezuelan military allegedly uses for drug trafficking, without providing evidence to the press. Trump denied a Miami Herald report that the "Trump Administration [had] made the decision to attack military installations inside Venezuela". On 31 October 2025, Newsweek reported that US ships were positioned near the Venezuelan military base at La Orchila Island, "within immediate operational range for amphibious or precision strike missions". The US Southern Command posted videos of live-fire drills by US Marines; satellite imagery confirmed the location to be the USS Iwo Jima, situated less than 200 kilometres (120 mi) off the coast of Venezuela and accompanied by two other USS destroyers. The US State Department designated Cartel of the Suns a Foreign Terrorist Organization effective 24 November 2025. The Miami Herald wrote: "The designation would effectively label Maduro and senior officials, including Interior Minister Diosdado Cabello and Defense Minister Vladimir Padrino López, as terrorists." The Trump administration said the designation "allows the US military the ability to target Maduro's assets and infrastructure inside Venezuela". A phone call between Trump and Maduro, including Rubio, occurred later in November, according to The New York Times.
SIRIUS is a Java-based open-source software for the identification of small molecules from fragmentation mass spectrometry data without the use of spectral libraries. It combines the analysis of isotope patterns in MS1 spectra with the analysis of fragmentation patterns in MS2 spectra. SIRIUS is the umbrella application comprising CSI:FingerID, CANOPUS, COSMIC and ZODIAC. SIRIUS, including its web services for structural elucidation, is freely available to use for academic research. Bright Giant GmbH offers subscription-based access to the SIRIUS web services for commercial users. SIRIUS is not suitable for analyzing proteomics MS data.
== Interactions == Co-administration of prednisolone eye drops with ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) may perhaps exacerbate its effects, causing unwanted side effects such as toxicity. The wound healing process may also be hindered. Drug interactions of prednisolone include other immunosuppressants like azathioprine or ciclosporin, antiplatelet drugs like clopidogrel, anticoagulants like dabigatran or warfarin, or NSAIDs such as aspirin, celecoxib, or ibuprofen.
Sources: en.wikipedia.org
=== Supercritical desalination === The solubility of dissolved ions drops precipitously once a fluid becomes supercritical. This effect can be used to precipitate salts from high salinity desalination streams, with solubility of different salts decreasing rapidly as water approaches supercritical temperatures. Complex cycle design can enable selective precipitation and improved heat recovery. Some very saline water sources like produced water also have high hydrocarbon content, which can be oxidized by supercritical desalination.
=== European Union === The European Union defines a VOC as "any organic compound as well as the fraction of creosote, having at 293.15 K a vapour pressure of 0.01 kPa or more, or having a corresponding volatility under the particular conditions of use;". The VOC Solvents Emissions Directive was the main policy instrument for the reduction of industrial emissions of volatile organic compounds (VOCs) in the European Union. It covers a wide range of solvent-using activities, e.g. printing, surface cleaning, vehicle coating, dry cleaning and manufacture of footwear and pharmaceutical products. The VOC Solvents Emissions Directive requires installations in which such activities are applied to comply either with the emission limit values set out in the Directive or with the requirements of the so-called reduction scheme. Article 13 of The Paints Directive, approved in 2004, amended the original VOC Solvents Emissions Directive and limits the use of organic solvents in decorative paints and varnishes and in vehicle finishing products. The Paints Directive sets out maximum VOC content limit values for paints and varnishes in certain applications. The Solvents Emissions Directive was replaced by the Industrial Emissions Directive from 2013.
== Future == The expansion of the genetic code is still in its infancy. Current methodology uses only one non-standard amino acid at the time, whereas ideally multiple could be used. In fact, the group of Jason Chin has recently broken the record for a genetically recoded E. coli strain that can simultaneously incorporate up to 4 unnatural amino acids. Moreover, there has been development in software that allows combination of orthogonal ribosomes and unnatural tRNA/RS pairs in order to improve protein yield and fidelity.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.